TELA Bio Q2 2025 revenue $20.2M (+26% YoY); net loss narrows to $9.9M; reaffirms FY2025 guidance $85M-$88M

TELA Bio, Inc.

2025-Q2 EPS reported -$0.47 vs consensus -$0.18 ▼ miss (-160.7%)

Revenue $20.2M (+26% YoY); OviTex PRS product revenue up 53% YoY.
Net loss $9.9M vs $12.6M in prior-year quarter; operating loss $9.1M improved from $11.6M.
Gross margin improved to 69.8% vs 68.8% due to lower excess/obsolete inventory charge.
Appointed Jeffrey Blizard as President effective June 2025 to strengthen commercial leadership.
Reaffirmed FY2025 revenue guidance of $85M-$88M (23-27% YoY growth); cash $35.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.